Adverum Biotechnologies, Inc. [NASDAQ:ADVM]: Analyst Rating and Earnings

Expert stock traders often make certain they pay attention what leading Wall Street analysts think regarding a potential stock purchase. As it relates to Adverum Biotechnologies, Inc. [ADVM] currently, the latest ratings from Wall St. experts that can be seen publicly is related to the fiscal quarter that’s scheduled to end in December. On average, stock market experts give ADVM an Hold rating. Its stock price has been found in the range of 2.62 to 8.18. This is compared to its latest closing price of $8.13.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Adverum Biotechnologies, Inc. [ADVM] is sitting at 2.60. This is compared to 1 month ago, when its average rating was 2.67.

Pay attention to the next-scheduled financial results for this company to be released, which is slated for Wed 14 Aug (In 89 Days).

Fundamental Analysis of Adverum Biotechnologies, Inc. [ADVM]

Now let’s turn to look at profitability: with a current Operating Margin for Adverum Biotechnologies, Inc. [ADVM] sitting at -4533.56.

This company’s Return on Total Capital is -37.94, and its Return on Invested Capital has reached -38.20%. Its Return on Equity is -37.71, and its Return on Assets is -34.97. These metrics suggest that this Adverum Biotechnologies, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

What about valuation? This company’s Enterprise Value to EBITDA is -3.00. The Enterprise Value to Sales for this firm is now 153.46. Adverum Biotechnologies, Inc. [ADVM] has a Price to Book Ratio of 0.99.

Shifting the focus to workforce efficiency, Adverum Biotechnologies, Inc. [ADVM] earns $19,659 for each employee under its payroll. Similarly, this company’s Total Asset Turnover is 0.01. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 19.48 and its Current Ratio is 19.48. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Adverum Biotechnologies, Inc. [ADVM] has 62.53M shares outstanding, amounting to a total market cap of $508.37M. Its stock price has been found in the range of 2.62 to 8.18. At its current price, it has moved by 4.16% from its 52-week high, and it has moved 225.19% from its 52-week low.

This stock’s Beta value is currently 3.19, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 77.12. This RSI suggests that Adverum Biotechnologies, Inc. is currently Overbought.

Conclusion: Is Adverum Biotechnologies, Inc. [ADVM] a Reliable Buy?

Shares of Adverum Biotechnologies, Inc. [ADVM], overall, appear to be a solid investment option, with Wall Street analysts expecting its price to rise considerably in the next 12 months. This company generates high value from the labor resources and other capital it has available, and while it has heavy Long-Term Debt to Equity, the majority of the metrics point to this investment being highly attractive.